Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study

Bagnoli, Marina; Canevari, Silvana; Califano, Daniela; Losito, Simona; Maïo, Massimo Di; Raspagliesi, Francesco; Carcangiu, Maria Luisa; Toffoli, Giuseppe; Cecchin, Erika; Sorio, Roberto; Canzonieri, Vincenzo; Russo, Daniela; Scognamiglio, Giosuè; Chiappetta, Gennaro; Baldassarre, Gustavo; Lorusso, Domenica; Scambia, Giovanni; Zannoni, Gian Franco; Savarese, Antonella; Carosi, Mariantonia; Scollo, Paolo; Breda, Enrico; Murgia, V.; Perrone, Francesco; Pignata, Sandro; Cecco, Loris De; Mezzanzanica, Delia

doi:10.1016/s1470-2045(16)30108-5

Cited by 100 publications

(119 citation statements)

References 45 publications

(38 reference statements)

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…We also observed the presence of miR-10a and 10b in publicly available data of normal fibroblasts and cancer associated fibroblasts, where the miR-10 family was equally expressed in both normal and cancer associated fibroblasts (33). A group of microRNAs expressed in ovarian cancer has been suggested to form a signature predictive of poor outcome in ovarian cancer patients (55); however, the only microRNA included in that signature that is also detected in the top five microRNAs in this study was miR-30d (Table 3). The role of microRNAs in ovarian cancer is still being investigated as is the role of tRFs.…”

Section: Discussionmentioning

confidence: 79%

A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis

Zhou

Spillman

Behbakht

et al. 2017

Analytical Biochemistry

View full text Add to dashboard Cite

Readily accessible samples such as urine or blood are seemingly ideal for differentiating and stratifying patients; however, it has proven a daunting task to identify reliable biomarkers in such samples. Noncoding RNA holds great promise as a source of biomarkers distinguishing physiologic wellbeing or illness. Current methods to isolate and characterize RNA molecules in urine are limited. In this proof of concept study, we present a method to extract and identify small noncoding RNAs in urine. Initially, quantitative reverse transcription PCR was applied to confirm the presence of microRNAs in total RNA extracted from urine. Once the presence of micro RNA in urine was confirmed, we developed a method to scale up RNA extraction to provide adequate amounts of RNA for next generation sequence analysis. The method described in this study is applicable to detecting a broad range of small noncoding RNAs in urine; thus, they have wide applicability for health and disease analyses.

show abstract

Section: Discussionmentioning

confidence: 79%

A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis

Zhou

Spillman

Behbakht

et al. 2017

Analytical Biochemistry

View full text Add to dashboard Cite

show abstract

“…In one study, RNA microarray expression data from the TCGA were used to investigate correlations between expression of specific miRNAs and mRNAs in ovarian cancer in order to identify potential mRNA targets of miRNAs [129]. Specific miRNA-based signatures or networks have been identified in epithelial ovarian cancers characterized by a poor prognosis, and have the potential to serve as prognostic markers in both early and advanced stages of the disease [130,131,132]. In addition, stable circulating cell-free miRNAs that closely mimic the miRNA profiles of tumor have been isolated from the serum and plasma of women with ovarian cancer [133].…”

Section: Implications Of the Molecular Characterization Of Epithelmentioning

confidence: 99%

Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment

Rojas

Hirshfield

Ganesan

et al. 2016

IJMS

180

166

View full text Add to dashboard Cite

Epithelial ovarian cancer is a highly heterogeneous disease characterized by multiple histological subtypes. Molecular diversity has been shown to occur within specific histological subtypes of epithelial ovarian cancer, between different tumors of an individual patient, as well as within individual tumors. Recent advances in the molecular characterization of epithelial ovarian cancer tumors have provided the basis for a simplified classification scheme in which these cancers are classified as either type I or type II tumors, and these two categories have implications regarding disease pathogenesis and prognosis. Molecular analyses, primarily based on next-generation sequencing, otherwise known as high-throughput sequencing, are allowing for further refinement of ovarian cancer classification, facilitating the elucidation of the site(s) of precursor lesions of high-grade serous ovarian cancer, and providing insight into the processes of clonal selection and evolution that may be associated with development of chemoresistance. Potential therapeutic targets have been identified from recent molecular profiling studies of these tumors, and the effectiveness and safety of a number of specific targeted therapies have been evaluated or are currently being studied for the treatment of women with this disease.

show abstract

“…2010-re már több száz olyan köz-lemény jelent meg, amelyek 70-50-30 génre tudták szűkíteni azokat a mintázatokat, amelyek egyes daganattípusokra vonatkozó fogékonyságot, egyes altípusok jelenlétét vagy kedvező és kedvezőtlen prognózis előrejel-zésében alkalmazhatónak bizonyultak. Petefészekrákkal kapcsolatban több száz beteg klinikai és egyenként mintegy 1000 különböző miRNS-expressziójára vonatkozó adataiból robusztus számítástechnikai elemzéssel sikerült egy 35 egyedi miRNS-re vonatkozó mintázatot kialakí-tani, amelyből egyszerű algoritmussal klinikailag releváns prognosztikai index határozható meg [60]. Az algoritmust egy szintén több száz klinikai esetet tartalmazó adatbázison validálva a szerzők meggyőzően igazolták az alacsony és magas rizikójú (HR>3) esetek elkülönítésé-nek lehetőségét a miRNS-mintázat alapján.…”

Section: Prognosztika éS Onkoterápiaunclassified

A „szabad” nukleinsavak jelentősége a noninvazív diagnosztikában

2016

View full text Add to dashboard Cite

Napjainkban nagy az érdeklődés a "szabad" nukleinsavak pontos élettani szerepének és klinikai diagnosztikai felhasználásának a meghatározására. A "szabad" nukleinsavak lehetnek DNS-, mRNS-, mikro-RNS-és hosszú nem kódoló RNS-(lncRNNA-) molekulák, amelyek megtalálhatók a testfolyadékokban, így például a szérumban, a nyálban, a könnyben. Az élettani szerepük kiderítése napjainkban is folyik, viszont egyre jelentősebb a diagnosztikai alkalmazhatóságuk. A magzati diagnosztikában a noninvazív módon történő mintavétel után nyert "szabad" DNS-t felhasználva több tesztet forgalomba hoztak, ezek specificitása és szenzitivitása eléri a 99,9%-ot. A szív-és keringési betegek korai diagnosztizálásában a "szabad" nukleinsavak meghatározása biztató eredményekkel szolgál. Az onkológiában a "folyadékbiopsziával" kapcsolatos közlemények megjelenése a más területen dolgozó egészségügyi szakemberek és a közvélemény figyelmét is felkeltette. Folynak a mikro-RNS szerepének és diagnosztikai alkalmazhatóságának a meghatározásai is. A "szabad" nukleinsavak új generációs szekvenálással történő felhasználására a korai diagnosztikában óriási az érdeklődés, de egyelőre nincs elég klinikai adat a lehetséges tesztek megbízhatóságáról és klinikai hasznossá-gáról. Orv. Hetil., 2016Hetil., , 157(48), 1900Hetil., -1909 Kulcsszavak: "szabad" nukleinsavak, DNS, mRNS, mikro-RNS, folyadékbiopszia, diagnosztika The importance of "free" nucleic acids in the non-invasive diagnosticsThere is a great interest to determine the physiological role of "free" nucleic acids, and to use them in the clinical diagnostics. These could be DNA, mRNA, microRNA and long non-coding RNA molecules, they are in the body fluids, like serum, tear, saliva, etc. Their exact role in the normal and pathological physiological processes is still in the focus of the research, while their use in the diagnostics is becoming more and more important. The use of "free" DNA in the non-invasive prenatal diagnosis is the first clinical application of the new generation sequencers, these methods are able to reach 99.9% specificity and sensitivity for the detection of the most common trisomies. There are promising results in their use in the diagnosis and classification of heart and cardiovascular diseases. In oncology the possibility to use the "liquid biopsy" captured the attention of not only researchers and clinicians, but the whole community. There is not enough data until today for the clinical utility and applicability of these methods.Keywords: "free" nucleic acids, DNA, mRNA, microRNA, liquid biopsy, diagnostics Nagy, B., Csanádi, Z., Póka, R. [The importance of "free" nucleic acids in the non-invasive diagnostics]. Orv. Hetil., 2016, 157(48), 1900-1909. (Beérkezett: 2016 elfogadva: 2016. október Rövidítések AMI = akut myocardialis infarctus; CNA = copy number gain; CRP = C-reaktív protein; CRT = szívreszinkronizációs terápia; ctDNS = keringő tumor-DNS; DNS = dezoxiribonukleinsav; EF = ejekciós frakció; HDL = high-density lipoprotein; LDL = low-density lipoprotein; lncRNA = (...

show abstract

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study

Cited by 100 publications

References 45 publications

A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis

A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis

Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment

A „szabad” nukleinsavak jelentősége a noninvazív diagnosztikában

Contact Info

Product

Resources

About